The drug pricing debate is top of mind with manufacturers, payers, governments, patients, and the medical professionals who treat them. In this issue of CRA Insights: Life Sciences we examine some of these issues.
Evaluating Medicare Stars for cardiovascular disease patients
Considering that cardiovascular disease (CVD) remains the leading cause of death in the United States, particularly affecting the growing population of...